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ABSTRACT 
Transdermal delivery system has been extensively employed over the years owing to its advantages over the conventional delivery 
systems. However, the stratum corneum hinders the penetration of substances through the skin. Microneedle technology is the 
latest advancement and has gained tremendous attention in transdermal delivery system, overcoming the obstacles of transdermal 
delivery system and providing advantages over the conventional delivery systems. Numerous studies have been carried out for 
exploring microneedles. This review article covers the types of microneedles, mechanism of action of microneedles, methodology 
of drug delivery via microneedles while mainly focusing on the applications of microneedles and their combination with other 
enhancing techniques in transdermal delivery of drug and other molecules.  
Keywords: Transdermal delivery, Microneedles, Stratum corneum, Iontophoresis, Electroporation, Sonophoresis, Vibratory 
actuation, Immunologicals, Biopharmaceuticals, Phlebotomy, Diagnosis. 
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1. INTRODUCTION 
Administration of drugs can be achieved through 
various possible delivery routes available including the 
most common routes like the oral, parenteral, 
ophthalmic and transdermal route, as well as less 
explored routes such as nasal, pulmonary and buccal 
1
. 
Each of these routes has specific merits and demerits. 
Over the years transdermal drug delivery systems have 
shown a potential alternative for the oral and 
parenteral routes of drug delivery systems overcoming 
their demerits of drug degradation in the 
gastrointestinal tract, first-pass metabolism, poor 
absorption, local irritation and variability in absorption 
(due to factors like pH, motility, food, mucus layer, 
etc.), in case of oral drug delivery systems 
2, 3
 and pain 
associated  with the injections, expertise required to 
deliver the drug, risk of infection and difficulty in 
obtaining sustained drug delivery in case of parenteral 
drug delivery systems
4.
 . However transdermal 
technology has limitations due to the inability of a 
large majority of drugs to cross the skin at the desired 
therapeutic rates because of the presence of a relatively 
impermeable thick outer stratum corneum layer. This 
barrier posed by human skin limits transdermal 
delivery only to lipophilic, low molecular weight 
potent drugs 
5
. Different strategies, including chemical 
and physical enhancers have shown, in many cases, a 
limited impact to overcome this disadvantage. In 
recent years, great attention has been paid to 
microneedles, a hybrid between hypodermic needles 
and transdermal patches to overcome the individual 
limitations of both the injections as well as patches. 
These are micron scale needles assembled on a 
transdermal patch, able to pierce and create micron 
sized pores in the skin to effectively deliver drugs in a 
painless manner through the stratum corneum, thus 
bypassing the most important permeability barrier of 
the skin. Microneedles have found application in the 
pharmaceutical field, not only to facilitate the 
administration of drugs with minimal invasion, but 
also for the extraction of biological fluids. Numerous 
studies have found a marked increase in drug transport 
through the skin when using microneedle arrays alone, 
in combination with other enhancers (e.g., 
iontophoresis or electroporation) or even when 
including more sophisticated devices such as 
micropumps. Microneedles have shown great 
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effectiveness in facilitating the passage of 
macromolecules, hydrophilic substances, and different 
carriers such as lipid vesicles and nanoparticles.  
2. CONCEPT OF MICRONEEDLES 
Microneedles are microstructured transdermal systems, 
consisting of an array of microstructured projections 
coated with a drug or vaccine that is applied to the skin 
to provide intradermal delivery of active agents, which 
otherwise would not cross the stratum corneum 
6
. 
Microneedles are somewhat like traditional needles, 
but are fabricated on the micro scale. They are smaller 
than hypodermic needle, generally one micron in 
diameter and ranges from 1-100 microns in length.  
 
Figure 1: Experimental microneedle array consisting 
400 microneedles. 
Advantages of Microneedles 
7-10
: 
 rapid onset of action 
 painless administration of the active 
pharmaceutical ingredient 
 Large molecules can be administered 
 first-pass metabolism is avoided 
 faster healing at injection site than with a 
hypodermic needle 
 patient compliance due to ease of administration 
 decreased microbial penetration as compared with 
a hypodermic needle, the microneedle bypasses 
the stratum corneum and punctures only the 
epidermis 
 specific skin area can be targeted for desired drug 
delivery 
 Drug can be administered at constant rate for a 
longer period 
 good reproducibility 
 good stability and enhanced drug efficacy may 
result in dose reduction 
 good tolerability without long-term oedema or 
erythema 
Disadvantages of Microneedles 
7
: 
 skin irritation may result because of allergy or 
sensitive skin 
 local inflammation may result if the concentration 
of drug is high under the skin 
 careful use of the device may be needed to avoid 
particles ‘bouncing off’ the skin surface; if the 
device is not held vertically, the dose may escape 
or can penetrate the skin to differing degrees 
 the thickness of the stratum corneum and other 
skin layers varies between individuals and so 
penetration depth of particles could vary too 
 external environment, like hydration of the skin, 
could affect delivery 
 tip of the microneedle may break off and remain 
within the skin on removal of the patch 
 Compressed dermal tissue can block hollow 
microneedles 
Selection of the material for constitution of the 
microneedle should be based on criteria such as gentle 
fabrication without damage to sensitive biomolecules, 
sufficient mechanical strength for insertion into skin 
and controlled or rapid drug release as per the 
requirement. Considering the requirement of 
microneedle to be long enough to penetrate the stratum 
corneum and at the same time should be short enough 
to be painless, they have been manufactured in a 
variety of shapes and sizes, as required for different 
applications using different materials as mentioned 
below 
11
. Most microneedle fabrication methods are 
based on the conventional microfabrication techniques 
of replicating microstructures using micromoulds, 
utilizing photolithographic processes, silicon etching, 
laser cutting, metal electroplating, metal 
electropolishing etc.  
3. MECHANISM OF ACTION 
The mechanism of action depends on the type of 
microneedle design. The general mechanism of 
delivery via microneedles is based on mechanical 
disruption of the skin and application of the drug or 
vaccine within the epidermis, from where it can more 
readily reach its targeted site of action. The drug is 
entrapped within the microneedles, which when 
inserted into the skin and releases the drug into the 
layers of skin which are highly vascularized. In some 
cases the needles dissolve within minutes, releasing 
the entrapped drug at the intended site of delivery from 
where they reach the target site. 
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Table 1: Material of construction for microneedles 
Material of 
construction 
Example Type of 
microneedle 
produced 
Merits Demerits 
Metal Nickel-iron 
11
, stainless steel 
12
, 
titanium 
13
,  
Hollow/solid/ 
coated 
Good mechanical 
strength, cost 
effective 
Non-
biodegradable, 
expensive, brittle 
Silicon Silicon dioxide 
14
 Solid/hollow Greater mechanical 
strength 
Expensive, brittle 
Glass ----- Hollow High drug loading 
capacity 
Non-
biodegradable 
Biodegradable 
Polymers 
Polylactic acid 
15
, Polyglycolic acid 
15
, 
Polylactide-co-glycolic acid (PLGA) 
15
,  polycarbonate
16
, 
Polyvinylpyrrolidone (PVP) 
17
 
Solid Cost effective, 
good resistance, 
biocompatible 
Thermal 
instability  
Non-
biodegradable 
polymers 
Polyvinyl acetate (PVA) 
18
, Alginic 
acid 
18
,  Gantrez AN-139, a copolymer 
of methylvinylether and maleic 
anhydride (PMVE/MA) 
18
, Carbopol 
971 P-NF 
18
, Polyetherimide 
19
 
Solid  Cost effective, 
good resistance 
Non-
biodegradable 
Polysaccharide
s 
carboxymethylcellulose 
20
, 
Amylopectin 
20
, Maltose 
21
, Dextran 
22
, Galactose 
22
, Chondroitin Sulfate 
22
, 
Thermoplastic starch 
23
 
Solid, 
dissolving 
Rapid drug 
delivery, 
biodegradable 
Hygroscopic, 
caramelization 
 
4. TYPES OF MICRONEEDLES 
Classification for microneedles usually used in 
literature is based on the fabrication process: in-plane or 
out-of-plane microneedles. 
Another useful point of distinction is whether the 
microneedles are solid, hollow, coated or dissolving. 
The following sections will give an overview of these 
microneedles. 
4.1 Solid microneedles 
Solid micro needles are defined as the arrays of 
projections that are employed for creating holes in 
stratum corneum and are applied before the application 
of a drug and then removed afterwards. These can 
essentially create micron scale holes in the skin, through 
which drug molecules can easily enter 
25
. These needles 
are inserted into the skin for specified time period. The 
micro channels developed by the insertion of micro 
needles promote the drug transport in to the viable 
epidermis 
26
.  
4.2 Coated microneedles 
Coated microneedles are solid microneedles that act as 
vehicles to carry and deposit drug within the skin or 
other tissue. This includes coating microneedles with a 
drug in a formulation suitable for coating and 
subsequent dissolution. In this way, the desired dose of 
the drug is delivered into tissue quickly upon insertion 
of the microneedles. The drug dose that can be 
administered this way is limited to the amount that can 
be coated onto the tip and shaft of the microneedles, 
which is typically less than 1 mg for small microneedle 
arrays
27
 
 4.3. Dissolving microneedles 
Unlike coated microneedles, dissolving microneedles 
completely dissolve in the skin and thus leave no bio 
hazardous waste behind after use. These microneedles 
typically constitute of water-soluble materials such as 
polymers and sugars that are safe and inert and will 
dissolve in the skin after insertion. While dissolving 
microneedles can be used as a skin pretreatment to 
increase permeability, drugs are often encapsulated 
inside the microneedle for release into the skin 
28
. 
4.4 Hollow microneedles 
Hollow microneedles contain a hollow bore in the 
center of the needle. When inserted into the skin, the 
hollow bore present bypasses the stratum corneum layer 
of the skin and produces a direct channel into the other 
lower layers of the epidermis 
26
.These microneedles are 
mainly employed to inject the drug solutions directly 
into the skin 
29
, to carry the drug into the body by 
diffusion 
30
. Similar to hypodermic injection, hollow 
microneedles enable pressure-driven flow of a liquid 
formulation. Pressure, and thereby flow rate, can be 
modulated for a rapid bolus injection, a slow infusion or 
a time-varying delivery rate. The apparent advantage of 
this is that a considerably larger amount of drug can be 
delivered for a given time, thus opening for applications 
where relatively large amounts are needed to obtain a 
therapeutic effect. The liquid formulation may simplify 
use of existing injectable formulations for delivery 
using microneedles, but misses the opportunity of solid 
microneedle delivery methods to administer dry-state 
drug formulations without reconstitution to improve 
drug stability and the patient convenience of a patch-
based delivery method. Hollow microneedles are also 
used to remove the fluid from the body for analysis
 30
. 
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Figure 2: Different types of microneedles: solid, coated, dissolving and hollow. 
 
4.5 Hydrogel-forming microneedles 
Hydrogel-forming microneedles are the latest 
development in microneedle technology. These are 
arrays of microneedles made up of a swelling material 
with a drug reservoir attached to the baseplate of the 
array 
31-34
. After insertion into the skin, the array 
absorbs interstitial fluid and swells to form continuous 
conduits between the dermal microcirculation and an 
attached patch-type drug reservoir leading to the 
diffusion of the drug into the skin 
32, 33
. Such 
microneedles act initially as a tool to penetrate the 
stratum corneum barrier. Upon swelling, they become a 
rate controlling membrane. These microneedle arrays 
are produced mainly using synthetic polymers such as 
an aqueous polymer gel that can be easily cross-linked 
by chemical or physical methods 
35
. These materials, 
once swollen, should maintain structural integrity and 
be reasonably robust during handling 
33
. Although 
hydrogel-forming microneedles are made from 
polymers, there are distinct differences between these 
microneedles and the regular dissolving polymer 
microneedles. Advantages of hydrogel-forming 
microneedles are that they can be fabricated in a wide 
range of patch sizes and geometries, can be easily 
sterilized, resist hole closure while in place and are 
removed completely intact from the skin 
32
. However 
more effort should be directed at widening the range of 
materials that can be used to fabricate these useful 
transdermal drug delivery systems. Hydrogel-forming 
MN arrays have been employed to deliver a wide range 
of different molecules from small molecules 
32-33, 36-37
 
to high molecular weight compounds 
32-33, 37
. The use 
of hydrogel-forming microneedle arrays for minimally-
invasive extraction and quantification of drug 
substances and glucose from skin in vitro and in vivo 
strongly illustrates the potential of hydrogel-forming 
microneedles in minimally-invasive patient monitoring 
and diagnosis 
38
. 
5. METHODOLOGY FOR DRUG DELIVERY 
A number of delivery strategies have been employed to 
use the microneedles for transdermal drug delivery. 
These include 
 Poke and patch  
 Coat and poke  
 Poke and release 
 Poke and flow 
5.1 Poke and patch
 
It involves piercing an array of solid microneedles into 
the skin followed by application of the drug patch at 
the treated site. Transport of drug across skin can occur 
by diffusion or possibly by iontophoresis if an electric 
field is applied 
39
. This technique was also tried to 
extract the interstitial fluid to measure the glucose level 
by non-invasive method 
40
.
  
5.2 Coat and poke 
In this approach needles are first coated with the drug 
and then inserted into the skin for drug release by 
dissolution. The entire drug to be delivered is coated on 
the needle itself 
5
. Dip and scrape approach is a 
variation of this approach, where microneedles are first 
dipped into a drug solution and then scraped across the 
skin surface to leave behind the drug within the micro 
abrasions created by the needles 
39
. A limited amount 
of drug could be coated over the microneedles (only 
about 1 mg) and extensive optimization was required 
for uniform coating in this ‘coat and poke’ approach. 
5.3 Poke and release 
It involves release of encapsulated drug into the skin 
from the microneedles made from polymers and 
polysaccharides that either slowly dissolves or 
degrades after administration.  Advantage of the ‘poke 
and release’ approach was that the drug release could 
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be modulated as per the requirement using a variety of 
available polymers and polysaccharides 
28
. 
5.4 Poke and flow 
In this approach first the skin is pierced (external 
pressure) and then the drug is allowed to flow through 
hollow microneedles from the reservoir in the patch 
41
. 
A large amount of drug can be administered by poke 
and flow method. Additionally, pressure-driven 
delivery adds the possibility to precisely steer the flow 
rate and to obtain a more controlled delivery. 
All of the above-mentioned approaches can be 
employed to deliver drugs either systemically or at a 
restricted site (local action). 
 
 
Figure 3 : Methodology for drug delivery by microneedles: (a) ‘poke and patch’ using solid microneedles, (b) ‘coat 
and poke’ using coated solid microneedles, (c) ‘poke and release’ using polymeric microneedles, (d) ‘poke and flow’ 
using hollow microneedles.  
 
6. APPLICATIONS OF MICRONEEDLES  
Microneedles have been explored for different 
applications and are extended to many fields. Owing to 
benefit of piercing in a minimally invasive manner, 
apart from being an alternative to conventional 
hypodermic therapy, they have also been employed for 
ocular, systemic and intracellular delivery. 
Microneedles can be used to deliver high molecular 
weight compounds like proteins and peptides, 
immunobiologicals like vaccines, antibodies etc. 
42
, 
bioactive agents or bio macromolecules like insulin, 
heparin, albumin, growth hormones 
43
. Microneedles 
have also gained prominent attention in the field of 
cosmetics and various cosmeceuticals have been used 
for the treatment of acne, pigmentation, scars and 
wrinkles as well as for skin toning 
42
.  
6.1 Immunobiologicals 
Attributing to the drawbacks of conventional 
vaccination procedure of needle phobia and the pain 
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associated with insertion of needle into the skin, recent 
studies have focused on development of needle-free 
vaccination like liquid jet injectors, powder injectors, 
thermal ablation and microneedles for the 
administration of immunobiologicals via the 
subcutaneous, intramuscular or intradermal route for 
prevention of infectious diseases. Microneedles have 
an edge over the other methods due to lack of pain, 
self-administration and quick delivery of vaccine 
42-43
. 
Making use of the microneedles allows vaccines to 
cross the stratum corneum and stimulate a clinical 
response. In case of dissolving microneedles, 
controlled and complete penetration is an important 
parameter to be considered. These are capable of 
delivering a small dose, less than several milligrams, of 
peptides, proteins, vaccines, hormones and organic 
compounds. Numerous studies have been performed 
and reported on vaccine delivery using microneedles 
including human IgG 
21
, tetanus toxoid 
23
, DNA 
vaccine 
39
, influenza vaccine 
44
, hepatitis B vaccine 
45
, 
human papilloma virus vaccine 
46
, west nile virus 
vaccine 
47
, chikungunya virus vaccine 
47
, herpes 
simplex virus vaccine 
48-49
, Bacillus Calmette Guerin 
vaccine 
50
, ovalbumin 
51
, , live attenuated chimeric JE 
vaccine (ChimeriVax)-JE/flavivirus vaccine 
52
, 
diphtheria 
53
, malaria 
53
, combination and recombinant 
protein vaccines for anthrax, botulism, plague and 
staphylococcal toxic shock 
54
. 
6.2 Bioactive macromolecules (Biopharmaceuticals) 
Owing to the proteolytic degradation and hindered 
absorption, bioactive macromolecules such as insulin, 
heparin, and growth hormones are not administered 
orally. The majority of commercially available 
biopharmaceuticals are administered via the parenteral 
route and hence a suitable non-invasive route is 
desirable. Microneedle arrays have been found to 
enhance the transport across dermatomed human skin 
for both low and high molecular weight compounds 
and also that the length of the microneedles and the 
depth up to which the microneedles penetrated in the 
skin had no effect on the transport of either low or high 
molecular weight compounds
55
. For rapid release as 
well as controlled release of molecules, an approach of 
preparing dissolving microneedles constituting water-
soluble polysaccharides has been done 
20, 22
. Studies 
performed and reported on administration of 
biopharmaceuticals using microneedles include 
delivery of low molecular weight heparin 
22
,  insulin 
56
, 
L-Carnitine 
57
, calcein and bovine serum albumin 
58
, 
desmopressin 
59
, recombinant human growth hormone 
and desmopressin 
60
, albumin 
61
, calcein 
62
, 
erythropoietin 
63
, oligonucleotides 
64
, porphyrin 
precursor 5-aminolevulinic acid (ALA) 
65
, salmon 
calcitonin 
66
, daniplestim 
67
, leuprolide acetate 
68
, Para 
thyroid hormone 
69
, human growth hormone 
70
 etc. 
6.3 Drugs 
It is essential for a drug molecule to possess the 
necessary physicochemical properties to cross the skin 
barrier.  Transport of a drug molecule through the skin 
and also the rate of transportation are governed by 
these physico-chemical properties like hydrophilic-
lipophilic balance, solubility, molecular weight, etc. 
The challenges posed in transdermal drug delivery can 
be overcome by use of microneedles. Use of 
microneedles enhances the bioavailability of drugs and 
can exclude the need for penetration enhancers, which 
may induce irritation. Microneedles may also reduce 
the side effects and complications associated with 
systemic administration. Drugs administered via 
microneedles include L-Ascorbic acid 
19
, riboflavin 
27
, 
galanthamine 
71
, aspirin 
72
, docetaxel 
73
, pilocarpine 
74
, 
methotrexate 
75
, prochlorperazine edisylate 
76
, lidocaine 
hydrochloride 
77
, ropinirole hydrochloride 
78,
 
ketoprofen 
79
, naltrexone with diclofenac sodium 
80
, 
phenylephrine 
81
, naltrexone 
82
, mannitol 
83
, glycerol 
84
 
etc. 
6.4 Phlebotomy 
Phlebotomy refers to the withdrawal of blood samples 
for analysis of specific blood constituents for diagnosis 
of a disease. Blood samples are generally collected 
from capillaries by pricking the skin or from veins 
using evacuated collection tube, depending on the 
volume of blood required for analysis. These methods 
are associated with disadvantages such as excessive 
bleeding, infection, scarring, fainting or feeling light-
headed. People may hesitate to give blood due to fear 
of needles and the moderate pain associated with the 
procedure. In such case, painless blood sampling using 
microneedles can be a very good alternative to 
hypodermic needles 
85-86
. Microneedles situated at a 
distance of 500–2000 mm in the dermis layer beneath 
the skin can be used to obtain precise body fluids as 
well as blood samples from the capillaries. Apart from 
making the procedure painless, microneedles also 
reduces the blood sample requirements (up to 200 
nanolitres). However the most essential requirement is 
that the microneedle must penetrate to sufficient depth; 
hence care should be taken in the design, material 
selection and dimensions of the microneedle, to ensure 
penetration at low pressure without breakage. Painless 
hollow microneedle-based micro sampling can be used 
instead of traditional methods for glucose estimation in 
case of disease diabetes which requires frequent 
monitoring of blood for estimation of glucose 
concentration or disease severity 
87
. Microneedles can 
also be used for monitoring of therapeutic drug levels 
88
. A jagged-shaped, hollow in-plane silicon 
microneedle resembling the proboscis of a mosquito 
has been prepared for collection of blood for testing 
89
. 
Arrays of 350m long, hollow, out-of-plane 
microneedles demonstrated in-situ analysis biological 
fluid extraction through capillary action 
90
. 
6.5 Diagnosis 
The use of microneedles can also be employed in the 
field of diagnosis. Hollow microneedles, along with 
quantum dots, help in medical diagnosis. Quantum dots 
are Nano scale crystals with a light-emitting property. 
The multiphoton microscopy method could rapidly 
diagnose cancers or other medical problems 
91
. Recent 
research focuses on the development of magnetic 
nanoparticles along with magnetic microneedle tips 
those safely collect biomarkers that indicate early-stage 
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osteoarthritis in knees, hips and other joints 
92
. Work 
has been carried out on development of two sensing 
device based on hybrid microneedles array for 
diagnostic and therapeutic applications. Hybrid 
microneedles having a porous structure were prepared, 
which can include a variety of biological molecules, as 
bioprobes or drugs. The first device is an 
electrochemical sensor where microneedles contain 
enzymes in their matrix that interact with glucose. The 
redox reaction with glucose, mediated by ferrocene, 
creates a charge transfer resulting in a current 
proportional to the glucose concentration. The second 
device is a therapeutic tool with optically controlled 
release of drug. In this case the device includes a 
porous silicon membrane with a Bragg's mirror, whose 
reflection wavelength is related to the drug’s 
concentration in the microneedle 
93
. Microneedle 
sensors fabricated at the end of an endoscope using 
poly caprolactone (PCL) microneedles coated with 
poly (3, 4-ethylenedioxythiophene) (PEDOT), 
functionalized with hemin molecules on the surface 
were employed for both endomicroscopic imaging and 
biosensing of colon cancer by real-time electrical 
detection of nitric oxide 
94
. Microneedles have also 
been developed as sensors for hydrogen peroxide, 
lactate, dissolved oxygen and glutamate 
95-97
. 
Microneedles have been employed as bioelectrical 
interfaces, especially for neural recording and 
stimulation 
98-106
, as well as for electrocardiography 
(ECG) 
107
 and electroencephalography (EEG) 
measurements 
108-109
. 
6.6 Cosmeceuticals 
Cosmeceutical industry has shown great interest in 
microneedle technology, the majority of cosmetic 
products are lending themselves to microneedle 
technology for non-surgical and non-ablative treatment 
of skin conditions such as ageing (wrinkles, lax skin), 
scarring (acne, surgical), photo damage, 
hyperpigmentation (age/brown spots) and hair loss 
(alopecia). The process facilitates and stimulates skin’s 
natural repair without causing permanent epidermal 
damage. Microneedles can be used for cosmetic 
applications, mainly for treatment of skin blemishes 
and the delivery of active cosmetic ingredients 
110-111
. 
Marketed microneedles like Derma rollers® and 
stamps are available for treatment of skin problems as 
well as to improve looks. MTS Dermaroller® marketed 
by Clinical Resolution Laboratory is a cosmetic aid 
possessing needles that penetrate the skin up to a depth 
of 0.2–0.3 mm. It contains 200 very fine stainless-steel 
needles that pierce the epidermis, creating a micro-
channel effect. Clinical studies from various countries 
have proven that therapeutic serum absorption is 
increased by as much as 1000 times when applied 
using the MTS Dermaroller® 
112
. A hyaluronic acid 
based dissolving microneedle patch developed for the 
intradermal delivery of ascorbic acid and retinyl 
retinoate displayed improved skin appearance in terms 
of roughness and wrinkle appearance when tested in 
human volunteers 
113
. An enhancement in the local 
delivery of eflornithine (used to reduce facial 
hirsutism) was observed both in vitro and in vivo when 
the skin was exposed to microneedle pretreatment 
followed by local administration of an eflornithine 
cream 
114
. Microneedle technology can be used to treat 
different types of scars by dermabrasion 
115-119
. 
Dermabrasion involves piercing the skin multiple times 
with microneedles to induce collagen growth. A 
noticeable improvement was observed in the treatment 
of patients with dermal scars (striae distensae) using a 
disc microneedle therapy 
116
. However, similar to the 
treatment of acne, this treatment too is associated with 
limitations of skin bleeding and painful treatment. An 
aesthetic improvement in patients with acne scars was 
reported with a reduction in scar severity in all subjects 
when treated with Dermaroller
®
 
117
. Similar results 
were obtained for treatment of atrophic facial scars 
using Dermarollers
®
 
120
. An alternative approach to the 
use of Dermarollers
®
 for the treatment of acne scars 
reported is the fractional radio frequency microneedle 
system. This system was introduced recently as a new 
device for facial rejuvenation. It involves creating 
radiofrequency-induced thermal zones. This causes 
damage to the reticular dermis followed by the dermal 
thickening. This system was clinically evaluated and 
the results suggested that this novel technique is 
efficacious for the treatment of acne scars, as it reduced 
the severity of the scars in more than 80% of 
volunteers 
121
. 
7. MICRONEEDLES IN COMBINATION WITH 
OTHER ENHANCING TECHNIQUES FOR 
IMPROVING TRANSDERMAL DRUG 
DELIVERY 
In order to improve the skin permeability, different 
techniques have been developed and employed such as 
using permeation enhancers, either chemical or 
physical. These enhancers may exhibit different 
mechanisms of action however their sole aim is to 
modify the structure of stratum corneum which is 
considered as the main barrier to the permeation of 
substances. Even though the use of permeation 
enhancers increases the penetration of drugs through 
the skin, in many cases it proves to be insufficient in 
achieving the therapeutic levels. To overcome this, 
several experiments in which two or even more 
enhancing techniques are combined have been 
attempted to obtain a synergistic effect, thus achieving 
the required effect of enhanced drug delivery and better 
control of drug delivery across the skin. Following 
section gives an overview of the enhancing techniques. 
7.1 Microneedles in combination with Iontophoresis 
The technique of transdermal iontophoresis involves 
the application of a physiologically acceptable low 
electric current (<0.5 mA/cm
2
) to the skin and works 
on the principle of “like repels like”, in order to 
promote the transfer of charged and polar substances 
across the stratum corneum of the skin 
122
. The barrier 
disruption thus caused by employing iontophoresis in 
combination with microneedles increases the 
possibility of variety of drugs that can be administered 
transdermally. It also allows achieving controlled 
delivery of drug by controlling the current
123
. 
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Iontophoretic transdermal transport mainly involves 
mechanisms of electromigration and electroosmosis. 
Electromigration is the movement of ionic species in 
response to the application of the electric field, and is 
the most important mechanism for the delivery of ionic 
drugs. Electroosmosis is the aqueous flow that occurs 
during the movement of charged species, carrying all 
the dissolved drugs across the skin. The technique of 
iontophoresis might be still limited by the molecular 
size of the drug candidate even though it offers an 
attractive alternative for the delivery of 
macromolecules 
124
. 
7.2 Microneedles in combination with Sonophoresis 
Sonophoresis involves application of ultrasound 
(frequency, 20 kHz to 10 MHz; intensity, up to 3 
W/cm
2
) causing perturbation of lipid bilayer inducing 
change in the lipid arrangement of the stratum 
corneum, forming cavitation thus enhancing 
transportation of drugs across the skin. Drug 
permeation can be controlled by controlling the 
frequency of the ultrasound. An increase in the sound 
frequency from 20 kHz to 1 MHz causes 1000 fold 
increase in skin perturbation 
125
. A synergistic effect on 
the permeation of molecules through the skin can be 
achieved by combining sonophoresis with 
microneedles. Very few studies have been performed 
on employing this strategy and thus needs to be 
explored further. 
7.3 Microneedles in combination with 
Electroporation 
Electroporation involves application of high voltage 
short-duration (milliseconds) current (generally 50–
1000 V/cm) causing a transitory, localized perturbation 
of lipid bilayer inducing structural rearrangements of 
the cell membrane due to the electric fields that are 
produced during current application. The aqueous 
pores formed as a result act as the aqueous pathways 
and provide a local driving force that facilitates the 
transport of molecules across the stratum corneum. A 
trans-membrane potential up to 1 kV for 10 ms to 500 
ms was used for in-vitro electroporation of stratum 
corneum 
125
. Although this process is useful for 
delivering large hydrophilic drug species like small 
molecules, proteins, peptides and oligonucleotides, 
including biopharmaceuticals with molecular weights 
greater than 7 kilo Daltons, electroporation was also 
used for permeation enhancement of larger molecules 
having molecular weight up to several kilo Daltons 
126
. 
Combining electroporation with microneedles resulted 
in microneedles that behaved as microelectrodes for 
electroporation, which eradicated the need for 
electrodes. This combination provides a synergistic 
effect on the permeation of molecules through the skin. 
7.4 Microneedles in combination with Vibratory 
actuation 
Precise control of insertion force is required for the 
penetration of a microneedle into the skin and it should 
not exceed the fracture force of the microneedle. 
Structure rigidity and miniaturization of microneedles 
should be well considered and a satisfactory balance 
between these two should be maintained. Vibration 
actuation causes tissue damage via fluid cavitation and 
thermal damage due to frictional interaction. When this 
mechanism of vibration actuation is combined with 
microneedles, a reduction in the microneedle insertion 
force is achieved as a result. A study employing this 
combination was performed wherein the combination 
of vibration actuation and microneedles helped in the 
preparation of microneedles using metals and polymers 
with low value of Young’s Modulus also the effect of 
vibratory actuation on microneedle insertion force was 
evaluated and greater than 70% reduction in the 
insertion force was observed 
127
.  
7.5 Microneedles in combination with Vesicles 
Several studies have been performed and reported on 
employing lipid vesicles for the transdermal drug 
delivery. However these systems are surrounded with 
controversy related to their delivery mechanism which 
is reported to be associated with the accumulation of 
the vesicle and the encapsulated drug in the stratum 
corneum because of their inability to penetrate the skin 
deep enough rendering them with little value as carriers 
for transdermal drug delivery. This paved the way for 
employing other vesicular systems which are able to 
penetrate into deeper skin layers, such as niosomes 
(vesicles composed of nonionic surfactants), ethosomes 
(vesicles with high alcohol content), transferosomes 
(vesicles composed of phospholipids as their main 
ingredient, with 10-25% surfactant and 3-10% 
ethanol), invasomes (vesicles formed by phospholipids, 
ethanol and terpenes as penetration enhancers) etc. 
Combining microneedles with these vesicular systems 
holds potential for enhanced transdermal drug delivery. 
Depending on the diameter and height of microneedles, 
liposomes can be located in different parts of the skin. 
Results may vary according to the needle geometries. 
Microneedles of short height render vesicles on the 
surface of the stratum corneum, while longer 
microneedles lead vesicles into deeper skin layers. 
7.6 Microneedles in combination with 
Microparticles and Nanoparticles 
The versatility of microparticles and nanoparticles for 
the effective and targeted release of different 
therapeutic agents to different anatomical regions 
makes them a good candidate as drug carriers or 
vehicles for topical and transdermal drug delivery for 
enhanced drug permeation 
128
. Microparticles and 
nanoparticles are distinct with respect to their size 
(micrometric and nanometric, respectively), 
biopharmaceutical properties and their therapeutic 
applications. These carriers can be constituted of 
biodegradable polymers or lipid materials. Penetration 
of nanoparticles through human skin depends on the 
nanoparticle size and shape, material properties etc. 
Nanospheres or nanocapsules of different sizes can be 
obtained by varying the materials employed and the 
method of preparation. A dramatic increase in cellular 
uptake can be achieved by reducing the size of 
nanoparticles. Few nanoparticle systems have a 
characteristic capability of diffusing into the cells, 
which makes them candidates to reach the drug target 
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in a specific cellular compartment. Combining 
microneedles with these nanoparticulate systems may 
significantly enhance the transdermal drug delivery 
wherein microchannels created by the microneedles 
may prove to be large enough to deliver drug-loaded 
nanostructures into the skin. Delivery of microparticles 
into the skin sets a challenge. In such case combining 
microneedles with these solid particles could facilitate 
the delivery of the later into the skin. By making use of 
appropriate microneedle design and insertion methods, 
even relatively large microparticles can be delivered 
into the skin. Perhaps the greatest shortcoming of 
controlled-release microneedles is that limited dose can 
be administered. Since the drug is encapsulated within 
microneedles and microneedles are, of course, very 
small, the maximum total dose that can be administered 
is likely to be less than 1 mg 
58
. 
7.7 Microneedles in combination with Micro pumps 
Conjunction of microneedles with micro pumps 
provide precise delivery of drug as the pumps control 
the flow rate and pressure for delivery of concentrated 
drug solution as required. This combination was 
employed in preparing an integrated system, with 
micro valves and micro-pumps, which was capable of 
controlling fluid withdrawal for medical analysis and 
delivering the drug in response to metabolites levels 
129
. 
7.8 Pocketed and Grooved Microneedles 
Modification of the microneedle surface can be 
employed for targeted drug delivery to a specific depth 
in the skin and for loading greater amount of drug onto 
the microneedle. This can be achieved by applying the 
protective coat or second drug coat on the same 
microneedles after filling the first part in the pockets. 
Such microneedles are known as pocketed 
microneedles. These can also be obtained by 
fabricating microneedles with one or more holes cut 
through the center 
130
. Also grooved microneedles that 
capable of loading greater amount of drug onto the 
microneedle can be employed for enhanced drug 
delivery 
131
. 
 
 
Table 2: Summary of few results of the delivery of drugs to the skin via microneedles in combination with 
carriers and/or enhancers 
S.N. Type of 
microneedle 
Enhancer Carrier Drug Model Result 
1 Coated 
microneedles 
2 
 
--------- 1-μm diameter 
barium sulfate 
particles and 
10-μm diameter 
latex particles 
 
-------- 
 
 
Porcine 
cadaver skin, 
in vitro 
 
Relatively large 
microparticles 
can be delivered into 
the skin for controlled 
drug release using 
appropriate microneedle 
design and insertion 
methods 
2 Solid stainless 
microneedle 
arrays 
12
 
 
Iontophoresis 
(0.2 mA/cm
2
) 
Nanovesicles Insulin 
 
Pig skin, in 
vitro 
Rats, in vivo 
 
Combination 
approach of 
microneedles and 
iontophoresis showed 
significant increase in 
the permeation of 
charged nanovesicles. 
Comparable levels to 
subcutaneous 
injection of insulin 
was achieved 
3 Beveled-tip 
and 
tapered-cone 
biodegradable 
polymeric  
microneedles
58
 
---------- 
 
carboxymethylc
ellulose or poly-
L: -
lactide micropar
ticles  
Calcein and 
bovine 
serum albumin 
Human 
cadaver skin 
and test in 
saline, in 
vitro 
 
Microneedles capable 
of encapsulating drug 
and providing 
controlled-release 
delivery in skin for 
hours to months. 
4 Macroflux® 
titanium or 
stainless Steel 
microprojection 
Array 
64
 
Iontophoresis 
(100 μA/cm2) 
 
------ Oligodeoxynu
cleotide 
ISIS 2302 
(ODNs) 
 
Hairless 
guinea 
pigs, in vivo 
 
Delivering ODNs into 
and through the skin 
in therapeutically 
relevant amounts 
5 Maltose 
microneedles
66
 
Iontophoresis 
(0.2 mA/cm
2 
for 1 hr ) 
-------- Salmon 
Calcitonin 
(SCT) 
Hairless rat 
skin, in vivo 
Transdermal delivery 
of SCT was achieved 
with highest delivery 
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   flux. 
6 Maltose 
Microneedles
67 
 
Iontophoresis 
(0.5 mA/cm
2
) 
------- Daniplestim Hairless rat 
skin, in vivo 
 
The combination 
approach yielded 
much higher flux 
values of daniplestim 
compared to 
iontophoresis alone 
7 Maltose 
microneedles
68
 
Iontophoresis 
(0.1 mA/cm
2 
for 4 hrs) 
------ Leuprolide 
acetate 
Hairless 
rats, in vivo 
The combination 
approach yielded 
much faster and 
higher flux values  of 
leuprolide acetate 
compared to 
iontophoresis and 
microneedles alone 
respectively 
8 Microneedle 
Array 
73
 
------- Elastic 
liposomes 
Docetaxel 
(DTX) 
 
Rat skin, in 
vitro  
Porcine 
skin, 
in vitro 
 
Microneedle 
treatment led to 
increased steady-state 
flux of DTX from all 
formulations and 
shorter lag time when 
applying elastic 
liposomes through 
microneedle 
9 Maltose 
Microneedles 
75
 
Iontophoresis 
(0.4 mA/cm
2
 
for 1 hr ) 
-------- Methotrexate 
 
Hairless rat 
skin, in vitro 
and in vivo 
Enhanced transdermal 
delivery of 
methotrexate both in 
vitro and in vivo. 
10 Dermaroller® 
76
 Iontophoresis 
(0.4 mA/cm
2 
) 
------ prochlorperazi
ne edisylate  
dermatomed 
human skin, 
in vitro 
Significantly 
enhanced the 
transdermal delivery 
of prochlorperazine 
edisylate 
11 AdminPatch®
78
 Iontophoresis  ------- Ropinirole 
hydrochloride 
Porcine ear 
skin, in vitro  
Continuous 
iontophoresis in 
combination with 
microneedles showed 
enhanced reflux of 
Ropinirole 
hydrochloride 
12 Dermarollers®
83 
 
---------- Invasomes Mannitol Human 
abdominal 
skin, in vitro 
 
Enhanced penetration 
and permeation of 
hydrophilic model 
drugs due to skin 
perforation by 
Dermarollers® 
particularly when 
combined with 
invasosome 
formulation. 
13 Microneedle 
roller 
85
 
Sonophoresis ------- Glycerol  Porcine 
skin, in vitro 
The combination 
method effectively 
enhanced transdermal 
delivery of glycerol 
by accelerating the 
diffusion rate through 
the skin barrier. 
14 Silicon 
microneedleele
ctrode  array
126
 
Electroporati
on  
 
 
------- Fluorescein 
isothiocyanate 
(FITC)-
dextran 
Male 
hairless rats, 
in vivo 
Enhanced permeation 
of FITC-dextran 
observed as a 
synergistic effect of the 
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 combination approach  
15 Hollow 
microneedles
127
 
Vibratory 
actuation 
------- ------- Excised 
animal skin, 
in vitro 
Greater than 70% 
reduction in 
microneedle insertion 
force by using 
vibratory actuation 
16 Pocketed solid 
stainless steel 
microneedle
130
 
----------- --------- Sulforhodamin
e, sodium 
fluorescein, 
luciferase 
plasmid DNA, 
vit B2 
Abdominal 
porcine 
cadaver 
skin, in vitro 
 
Rapid release of the 
model drugs at a 
targeted depth 
in the skin.  
17 Grooves-
embedded 
microneedle 
arrays of 
poly-L-lactic 
acid 
131
 
------------ ------- Ovalbumin Mice, in 
vivo 
Microneedles coated 
with ovalbumin 
render higher 
antibody response as 
the number and depth 
of grooves increase 
18 Maltose 
Microneedles
132
 
Iontophoresis 
(0.5 mA/cm
2
) 
------ Low mol. wt 
heparin 
(LMWH) 
Hairless rat 
skin, in vitro 
Increased skin 
permeation of 
LMWH 
19 Microneedle 
Array 
133
 
Iontophoresis 
(0.3 mA/cm
2
) 
------ FITC-dextrans Hairless rat 
skin, in vitro 
Enhanced transdermal 
delivery of dextrans 
20 Silicon and 
glass hollow 
microneedle 
array 
134
 
Sonophoresis  -------- Calcein and 
bovine serum 
albumin 
(BSA) 
Pig skin, in 
vitro 
In vitro results 
showed a significant 
improvement in the 
delivery rate even 
when large molecular 
weight compounds 
were used. 
21 Stainless steel 
& silicon solid 
microneedles
135
 
Sonophoresis -------- FITC-dextrans excised 
porcine skin, 
in vitro 
Significantly 
increased skin 
permeation of FITC-
dextrans. 
22 Stainless steel 
solid 
microneedles 
136
 
Sonophoresis  Cross-linked 
hydrogelof 
NaCMC and gel 
emulsion 
Lidocaine  Porcine 
skin, in vitro 
Slight increase in the 
permeability of 
lidocaine due to the 
combination 
approach. 
23 Dissolving 
microneedles
137
 
Electroporati
on 
------- p2CMVmIL-
12 
Mice, in 
vivo  
in-situ cutaneous 
transfer of 
p2CMVmIL-12 to 
successfully treat 
B16F10 subcutaneous 
tumors 
24 Silicon 
microneedle 
electrode 
arrays 
138 
 
Electroporati
on 
------- ------- -------- A uniform drug 
release through 
hollow microneedle 
electrodes into tissue 
is expected to be 
achieved during 
electroporation. 
25 Coated 
microneedle 
array 
139
 
Electroporati
on 
------- Plasmid DNA Mice, in 
vivo 
Robust antibody 
responses.  
26 
 
Solid 
microneedles
140
 
-------- L595 vesicles 
(composed of 
sucrose-laurate 
ester & 
octaoxyethylene
-laurate ester) 
and sPC 
hepatitis B 
surface antigen 
(HBsAg) 
Mice, in 
vivo 
Successful 
transcutaneous 
immunization (TCI) 
of hepatitis B surface 
antigen (HBsAg) 
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vesicles 
(composed of 
soybean–
phosphatidylchol
ne and Span-
80)  
27 Solid 
microneedles
141
 
------- anionic 
surfactant-based 
vesicles 
diphtheria 
toxoid 
 BALB/c 
mice, in 
vivo 
Enhancement in the 
immunogenicity of 
topically applied 
diphtheria toxin due 
to microneedle 
pretreatment 
28 Dermaroller® 
142
 
-------- liposomes -------- Human skin, 
iv vitro 
Evaluation of potential 
of Dermaroller®, with 
different needle 
geometries, to deliver a 
lipophilic fluorescent 
compound 
encapsulated in 
liposomes across the 
human skin 
29 Nanopore 
turbo roller 
143
 
-------- nanoliposomes sepia melanin Human skin, 
iv vitro 
Accelerates the 
delivery of melanin 
into hair structures 
allowing an even 
absorption, larger 
pigment deposits, and 
deeper penetration of 
the formulation into 
the hair. 
30 Silicon 
microneedle 
arrays 
144
 
-------- Polystyrene 
nanospheres  
------- Human skin, 
iv vitro 
Potential for 
significant 
enhancement the 
intra/transdermal 
delivery of 
nanoparticle 
formulations. 
31 Solid silicon 
microneedle 
arrays 
145
 
--------- poly(d,l-lactic-
co-glycolic 
acid) (PLGA) 
nanoparticles 
------- Human skin, 
iv vitro 
Permeation of 
nanoparticles into the 
skin was enhanced by 
microneedles 
32 Microneedle 
arrays 
146
 
-------- Microparticles  Gene -------- Microneedles 
increase the 
penetration depths of 
the particles. 
33 Hollow 
microneedle 
147
 
-------- nanoparticle 
and 
microparticle 
suspensions  
------- whole 
rabbit, pig, 
and human 
eyes ex vivo 
Microneedles were 
shown for the first 
time to deliver 
nanoparticle and 
microparticle 
suspensions into the 
suprachoroidal space 
of rabbit, pig and 
human eyes. 
34 Solid silicon 
microneedle 
Arrays 
148
 
  
----------- Polystyrene 
latex 
nanospheres 
 
--------- Human 
cadaver 
epidermis, 
in vitro 
A significant number 
of latex nanoparticles 
cross the skin. 
35 Silicon 
microneedle 
arrays 
149
 
---------- Fluorescent 
latex 
nanospheres 
 
----------- Human skin, 
in vitro 
Topical application of 
nanospheres followed 
by the microneedle 
treatment resulted 
in the migration of the 
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charged fluorescent 
particles into the 
microchannels, & to 
the cells of the viable 
epidermis 
36 Silicon-based 
Microneedles
150 
 
-------------- Fluorescent 
polystyrene 
nanospheres 
 
Lipid: polycati
on : pDNA 
(LPD) 
nonviral gene 
therapy 
vectors. 
 
Heat-
separated 
human 
epidermal 
sheets, in 
vitro 
 
Microneedle 
membrane treatment 
resulted in enhanced 
diffusion of 
fluorescent 
polystyrene 
nanospheres  
37 Silicon 
Microneedles
151 
 
----------- Hydrogel / 
Fluorescent 
Nanoparticle 
Loaded 
 
--------- Human skin, 
in vitro 
 
Microneedle 
treatment resulted in 
successful targeting 
of nanoparticles 
within the viable 
epidermis  
38 Hollow 
Microneedles
152
 
------------- Nanospheres of 
PLA with Nile 
red and latex 
fluorescein 
labeled 
microspheres 
--------- Human 
corpse 
sclera, in 
vitro 
 
Successful delivery of 
soluble molecules and 
nanoparticle 
Suspensions into the 
sclera.  
39 Pocketed 
stainless steel 
microneedles
153
 
----------- --------- Botulinum 
toxin A (BT) 
Excised 
human skin, 
in vitro 
Microneedles provide 
less invasive 
alternative that is 
suited to delivery of 
large proteins such as 
BT. Microneedles 
were not only able to 
accommodate 
therapeutic doses of a 
model protein but 
they were also able to 
deliver an inactivated 
form of the toxin into 
human skin. 
40 Coated 
microneedles
154
 
---------- Poly(lactic-co-
glycolic) acid 
(PLGA) 
nanoparticles  
Doxorubicin  porcine 
cadaver 
buccal 
tissues, in 
vitro  
Coated microneedles 
provide uniform and 
effective delivery of 
drugs to localized oral 
cancers. 
41 Silicon 
microneedles
155
 
----------- Hypoxia-
sensitive 
hyaluronic acid-
based vesicles 
Insulin Mice, in 
vivo 
Glucose responsive 
vesicles loaded 
microneedles provided 
convenient, painless, 
and continuous 
administration of 
insulin. They were 
found to be responsive 
to glucose challenge 
and also efficiently 
minimized the risk of 
hypoglycemia in the in 
vivo glucose tolerance 
test. 
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42 Silicon 
microneedles
156
 
---------- Lipid 
microparticles 
Quercetin Pig skin, in 
vitro 
Compared to intact 
skin, a marked 
increase in quercetin 
levels permeated into 
the stratum corneum 
and viable epidermis 
was achieved when 
skin was treated with 
the flavonoid-loaded 
LMs in combination 
with microneedle 
arrays 
43 Solid silicon 
microneedles
157
 
----------- Poly-D, L-lactic 
acid (PDLLA) 
nanoparticles 
Ketoprofen  Porcine 
skin, in vitro 
An enhanced flux of 
ketoprofen was 
observed in the skin 
treated with silicon 
microneedles over a 
prolonged period of 
time. 
 
 
CONCLUSION 
Various research studies carried out on microneedles 
are evident enough to state that microneedles are the 
efficient and potential transdermal delivery systems. 
They have been gaining a lot of importance due to 
their key advantages over the conventional delivery 
systems of being safe, convenient and painless. 
Microneedles have proved to be the solution for 
overcoming the barrier imposed by the stratum 
corneum, thus broadening the number of drugs and 
other molecules to be administered by this route. 
Extensive work has been carried out to create advances 
and to explore the wide applications of microneedles. 
Apart from playing the vital role in transportation of 
numerous drug molecules including poorly permeable 
ones, macromolecules and biopharmaceuticals, 
microneedles have also been applied in phlebotomy, 
diagnosis and cosmeceuticals. Numerous studies have 
been performed and reported on the synergistic effect 
of combining microneedles with other techniques for 
enhanced drug delivery such as sonophoresis, 
electroporation, iontophoresis, vibratory actuation etc. 
and have turn out to be beneficial in efficient 
transportation of drug and other macromolecules 
across the skin. Conjugating microneedles with 
carriers such as vesicles, nanoparticles, microparticles 
etc. allows achieving a controlled delivery of drug 
molecules. Precise drug delivery has been possible by 
employing microneedles in combination of micro 
pumps while greater amount of drug can be delivered 
by loading into the pocketed and grooved 
microneedles. Thus it was concluded that microneedles 
are more efficient as compared to the hypodermic 
needles and the other conventional delivery systems. 
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